|
US7105159B1
(en)
|
1992-11-05 |
2006-09-12 |
Sloan-Kettering Institute For Cancer Research |
Antibodies to prostate-specific membrane antigen
|
|
US6953668B1
(en)
|
1992-11-05 |
2005-10-11 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
US7070782B1
(en)
|
1992-11-05 |
2006-07-04 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
US6569432B1
(en)
|
1995-02-24 |
2003-05-27 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen and uses thereof
|
|
ATE317435T1
(de)
|
1995-02-24 |
2006-02-15 |
Sloan Kettering Inst Cancer |
Prostataspezifisches membranes antigen und seine anwendungen
|
|
US7381407B1
(en)
|
1996-03-25 |
2008-06-03 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US6150508A
(en)
*
|
1996-03-25 |
2000-11-21 |
Northwest Biotherapeutics, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US6962981B1
(en)
|
1996-03-25 |
2005-11-08 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
US6107090A
(en)
|
1996-05-06 |
2000-08-22 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
|
|
US6207805B1
(en)
|
1997-07-18 |
2001-03-27 |
University Of Iowa Research Foundation |
Prostate cell surface antigen-specific antibodies
|
|
GB2328871A
(en)
*
|
1997-09-05 |
1999-03-10 |
Merck & Co Inc |
Compositions for inhibiting platelet aggregation
|
|
WO1999043710A1
(en)
*
|
1998-02-26 |
1999-09-02 |
Beckman Coulter, Inc. |
Prostate-specific membrane antigens and methods of making and using
|
|
AU757698C
(en)
*
|
1998-06-01 |
2004-04-08 |
Agensys, Inc. |
Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
|
|
US20030035798A1
(en)
*
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
|
SE9900495D0
(sv)
*
|
1999-02-12 |
1999-02-12 |
Pharmatrix Ab |
Vaccine composition
|
|
WO2000050457A1
(en)
*
|
1999-02-22 |
2000-08-31 |
Beckman Coulter, Inc. |
Prostate-specific membrane antigens and methods of making and using
|
|
EP1710256A1
(en)
*
|
1999-07-29 |
2006-10-11 |
Medarex, Inc. |
Human monoclonal antibodies to prostate specific membrane antigen
|
|
CA2380783C
(en)
*
|
1999-07-29 |
2009-01-27 |
Yashwant Deo |
Human monoclonal antibodies to prostate specific membrane antigen
|
|
FR2797743B1
(fr)
*
|
1999-08-23 |
2003-08-08 |
Urogene |
Lignee cellulaire prostatique et son utilisation pour l'obtention d'une tumeur prostatique etablie chez l'animal
|
|
WO2001019956A2
(en)
*
|
1999-09-13 |
2001-03-22 |
Bander Neil H |
A method for isolation of prostatic epithelial cells from semen
|
|
JP4838436B2
(ja)
*
|
2001-04-04 |
2011-12-14 |
積水メディカル株式会社 |
抗ヒト肝性トリグリセリドリパーゼ抗体
|
|
EP2277542B1
(en)
|
2001-06-01 |
2014-04-16 |
Cornell Research Foundation Inc. |
Modified antibodies to prostrate-specific membrane antigen and uses thereof
|
|
US7514078B2
(en)
|
2001-06-01 |
2009-04-07 |
Cornell Research Foundation, Inc. |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
|
|
IL159422A0
(en)
|
2001-09-20 |
2004-06-01 |
Cornell Res Foundation Inc |
Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
|
|
US20040161776A1
(en)
*
|
2001-10-23 |
2004-08-19 |
Maddon Paul J. |
PSMA formulations and uses thereof
|
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
|
WO2003034903A2
(en)
|
2001-10-23 |
2003-05-01 |
Psma Development Company, L.L.C. |
Psma antibodies and protein multimers
|
|
ATE408712T1
(de)
|
2003-01-10 |
2008-10-15 |
Millennium Pharm Inc |
Verfahren zur bestimmung des wiederauftretens von prostata krebs
|
|
BRPI0607796A2
(pt)
|
2005-02-18 |
2009-06-13 |
Medarex Inc |
composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
|
|
CA2603093A1
(en)
*
|
2005-03-31 |
2006-10-05 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161p2f10b proteins
|
|
EP1726650A1
(en)
*
|
2005-05-27 |
2006-11-29 |
Universitätsklinikum Freiburg |
Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
|
|
CA2623236A1
(en)
|
2005-09-26 |
2007-04-05 |
Medarex, Inc. |
Human monoclonal antibodies to cd70
|
|
WO2007109321A2
(en)
|
2006-03-20 |
2007-09-27 |
The Regents Of The University Of California |
Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
|
|
US8940298B2
(en)
|
2007-09-04 |
2015-01-27 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
|
|
WO2009106101A1
(en)
*
|
2008-02-29 |
2009-09-03 |
Interuniversitair Microelektronica Centrum |
Cell-enzyme based biosensors
|
|
EP2326350B1
(en)
|
2008-09-08 |
2013-09-04 |
Psma Development Company, L.L.C. |
Compounds for killing psma-expressing, taxane-resistant cancer cells
|
|
EP2398504B1
(en)
|
2009-02-17 |
2018-11-28 |
Cornell Research Foundation, Inc. |
Methods and kits for diagnosis of cancer and prediction of therapeutic value
|
|
CA2782333C
(en)
|
2009-12-02 |
2019-06-04 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
|
KR102023496B1
(ko)
|
2011-04-21 |
2019-09-20 |
시애틀 지네틱스, 인크. |
신규 결합제-약물 콘주게이트 (adc) 및 그의 용도
|
|
UA118950C2
(uk)
|
2011-04-22 |
2019-04-10 |
Аптево Рісьорч Енд Девелопмент Ллс |
Поліпептид, який зв'язує специфічний мембранний антиген простати та комплекс т-клітинного рецептора
|
|
PL3086814T3
(pl)
|
2013-12-23 |
2020-12-28 |
Bayer Pharma Aktiengesellschaft |
Koniugaty środka wiążącego (ADC) z inhibitorami KSP
|
|
RU2751512C2
(ru)
|
2015-06-22 |
2021-07-14 |
Байер Фарма Акциенгезельшафт |
Конъюгаты антитела и лекарственного средства (adc) и конъюгаты антитела и пролекарства (apdc), содержащие ферментативно расщепляемые группы
|
|
JOP20160154B1
(ar)
*
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
WO2017027325A1
(en)
|
2015-08-07 |
2017-02-16 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
|
EP3352760B1
(en)
|
2015-09-21 |
2026-03-11 |
Aptevo Research and Development LLC |
Cd3 binding polypeptides
|
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
|
AU2017236431A1
(en)
|
2016-03-24 |
2018-09-27 |
Bayer Pharma Aktiengesellschaft |
Prodrugs of cytotoxic active agents having enzymatically cleavable groups
|
|
WO2017216028A1
(en)
|
2016-06-15 |
2017-12-21 |
Bayer Pharma Aktiengesellschaft |
Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
|
|
CA3047491A1
(en)
|
2016-12-21 |
2018-06-28 |
Bayer Aktiengesellschaft |
Prodrugs of cytotoxic active agents having enzymatically cleavable groups
|
|
JP7066714B2
(ja)
|
2016-12-21 |
2022-05-13 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
|
|
JP7030811B2
(ja)
|
2016-12-21 |
2022-03-07 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ）
|
|
MX2020009272A
(es)
|
2018-03-06 |
2021-01-08 |
Univ Pennsylvania |
Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
|
|
SG11202012342WA
(en)
|
2018-06-18 |
2021-01-28 |
Eureka Therapeutics Inc |
Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
|
|
SG11202100607RA
(en)
|
2018-07-31 |
2021-02-25 |
Heidelberg Pharma Res Gmbh |
Humanized antibodies against psma
|